Janssen Takes Another 'Patent Dance' Step In Remicade Case
Law360, Boston (June 1, 2017, 4:15 PM EDT) -- Janssen Biotech Inc. on Wednesday filed a new lawsuit in Massachusetts federal court over Celltrion’s biosimilar for the blockbuster Remicade, yet another step in the so-called patent dance in their long-running dispute.
The new suit, Janssen told Senior U.S. District Judge Mark Wolf, contains essentially the same allegations they've been fighting over for months. It wasn’t even necessary under the Biologics Price Competition and Innovation Act, Janssen said. But defendants Celltrion and Pfizer company Hospira have said that Janssen wouldn’t be able to get lost profit damages without filing the new suit.
“Although Janssen strongly disagrees with defendants’ position, filing the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!
Kirkland & Ellis LLP has redefined what it means to be the biggest of BigLaw — weighing in at 2,116 attorneys by year end 2018 and becoming the first firm since Law360 began tracking law firm head counts to top 2,000 U.S.-based attorneys.